Anthony S. Fauci, MD to Deliver Keynote Address During the 2020 American Urological Association Virtual Experience

June 11, 2020

Anthony S. Fauci, MD will be the Association’s keynote speaker during American Urological Association (AUA) Live, a component of the Association’s 2020 Virtual Experience. Dr. Fauci’s keynote address will take place on Saturday, June 27, at 11:30 a.m. (ET).

Anthony S. Fauci, MD is one of the most visible faces of the U.S. response to the coronavirus pandemic, the National Institute of Allergy and Infectious Diseases (NIAID) director who will provide an update on COVID-19, as well as the research community’s response to the pandemic.

“We are very excited to welcome Dr. Fauci as part of the 2020 AUA Virtual Experience, and his presentation could not be more timely,” said John D. Denstedt, MD, Secretary of the AUA Board of Directors. “He will set the tone for the important work being done every day to manage COVID-19 and reflect on the impact it has had on the urology community, as well as the broader medical community.”

Dr. Fauci is one of the most prominent members of the White House Coronavirus Task Force and has advised six U.S. Presidents on many domestic and global health issues, including HIV/AIDS for more than three decades. He is the recipient of numerous prestigious awards, including the Presidential Medal of Freedom (the highest honor given to a civilian by the President of the United States).

“To date, there have been more than 7.1 million reported cases of COVID-19 around the world and about 410,000 confirmed deaths,” said Denstedt. “Hearing more from Dr. Fauci about a collaborative approach to the clinical testing, scaling capacity and distribution of candidate vaccines to prevent COVID-19 is important to our members and to promoting the highest standards of clinical care.”

Dr. Fauci has served as the director of the NIAID since 1984 and oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as tuberculosis, malaria, respiratory infections, as well as emerging diseases such as Ebola and Zika. Additionally, he supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.

The AUA continues to be a leader in developing innovative, evidence-based quality education for urologists and urologic health care professionals worldwide. Through the AUA Virtual Experience—and other year-round educational offerings—the AUA sets the highest standards for urologic education and provides unparalleled access to groundbreaking research, new guidelines and the latest advances in urologic medicine. Register here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version